Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    E2408
Previous Study | Return to List | Next Study

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2014 by Eastern Cooperative Oncology Group.
Recruitment status was  Recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group Identifier:
First received: October 6, 2010
Last updated: March 13, 2015
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)